MicuRx Pharmaceuticals
MicuRx Pharmaceuticals, founded in 2007 and headquartered in Shanghai, specializes in the development of novel drugs for infectious diseases, particularly targeting drug-resistant bacterial infections.
Company History
MicuRx Pharmaceuticals was founded in 2007. It is headquartered in Shanghai, with branches in California, Hong Kong, and Beijing. The company specializes in the design, discovery, and development of novel drugs aimed at treating infectious diseases and addressing unmet medical needs.
Product Pipeline
MicuRx Pharmaceuticals' pipeline includes a variety of investigational medicines. Contezolid (MRX-I), supported by National Major Scientific and Technological Special Projects from the 11th to 13th five-year periods, and Contezolid acefosamil (MRX-4) are among its key antibiotics. MRX-8 targets multidrug-resistant Gram-negative bacteria, while MRX-5, MRX-7, MRX-15, MRX-17, and MRX-18 focus on various infections and targeted therapies.
Focus Areas
The primary focus of MicuRx Pharmaceuticals is the discovery and development of novel antibiotics for drug-resistant bacterial infections. The company targets next-generation safe and effective antibiotics to combat multidrug-resistant super bacteria. Additionally, MicuRx works on treatments for cancer and inflammation.
Clinical Trials
MicuRx Pharmaceuticals launched a Phase III clinical trial of the injection MRX-4 in China for complex skin and soft tissue infections. The company's investigational drugs, Contezolid (MRX-I) and Contezolid acefosamil (MRX-4), have received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation, underscoring their potential impact on public health.
FDA Designations
MicuRx Pharmaceuticals' lead products, Contezolid (MRX-I) and Contezolid acefosamil (MRX-4), have been granted FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations. These designations highlight their importance in addressing critical medical challenges related to drug-resistant bacteria.